Posterior segment inflammation with venous involvement following a switch to a ranibizumab biosimilar (Ximluci®): a case report. [PDF]
Am J Ophthalmol Case RepConte S +4 more
europepmc +1 more source
Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review. [PDF]
Endocrinol Diabetes MetabHindley B +4 more
europepmc +1 more source
Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. [PDF]
Saudi Pharm JShan H +5 more
europepmc +1 more source
Biosimilars Market Intelligence and Financial Forecasting | Agenda Released!
, 2013 CBIs Biosimilars
core
Determinants of access to anticancer medicines in South Asia: a multimethod study. [PDF]
BMJ OpenShukar S +12 more
europepmc +1 more source
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]
Pharmaceuticals (Basel)Ponamarev VS.
europepmc +1 more source
Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study. [PDF]
Sci RepSong JR +11 more
europepmc +1 more source
Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology. [PDF]
Inflamm Bowel DisColwill M +4 more
europepmc +1 more source
Expanding Horizons in Severe Asthma: Anti-IgE Biosimilars and the Redefinition of Patient Selection. [PDF]
Allergy Asthma Immunol ResYun JE, Song WJ.
europepmc +1 more source